Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL

By Hailey Konnath · September 30, 2026, 12:04 AM EDT

A New Jersey federal judge Tuesday refused to throw out sprawling antitrust multidistrict litigation over Celgene Corp.'s cancer drug Revlimid filed against Bristol-Myers Squibb, Natco Pharma, AbbVie and other pharmaceutical companies,...

To view the full article, register now.

Documents

Case Information

Case Title

IN RE REVLIMID & THALOMID PURCHASER ANTITRUST LITIGATION

Case Number

2:19-cv-07532

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

March 01, 2019


Case Title

UNITED HEALTHCARE SERVICES, INC. v. CELGENE CORPORATION

Case Number

2:20-cv-18531

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

December 08, 2020